Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90-Yttrium versus 177-Lutetium – Comparison of clinico-pathological and survival outcomes

#3880

Introduction: The role of peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment in patients with is still controversial, although recent experiences showed encouraging results in terms of oncological outcomes.

Aim(s): To compare postoperative clinico-pathological outcomes between patients who underwent preoperative PRRT with 90-Yttrium (90Y) or 177-Lutetium (177Lu).

Materials and methods: Consecutive patients with NF-PanNETs who underwent surgery between 2009 and 2021 at IRCCS San Raffaele Hospital after neoadjuvant PRRT with 90Y, 177Lu or combined 90Y/177Lu were included.

Conference:

Presenting Author: Genova L

Authors: Genova L, Andreasi V, Partelli S, Muffatti F, Battistella A,

Keywords: peptide receptor radionuclide therapy, prrt, neoadjuvant, surgery, yttrium, lutetium,